-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Merck & Co.'s Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$48.70 B | $59.28 B | $60.12 B | $64.17 B | $65.01 B |
| Cost of Revenue |
|
$13.63 B | $17.41 B | $16.13 B | $15.19 B | $12.03 B |
| Gross Profit |
|
$35.08 B | $41.87 B | $43.99 B | $48.98 B | $52.98 B |
| Research & Development |
|
$12.25 B | $13.55 B | $30.53 B | $17.94 B | $15.60 B |
| Selling,General & Administrative |
|
$9.40 B | $9.67 B | $9.88 B | $10.10 B | $10.61 B |
| Operating Expense |
|
$21.88 B | $23.59 B | $41.04 B | $28.75 B | $26.21 B |
| Operating Income |
|
$13.20 B | $18.28 B | $2.95 B | $20.22 B | $26.78 B |
| Net Income |
|
$13.05 B | $14.52 B | $365.00 M | $17.12 B | $18.25 B |
Merck & Co.'s Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.10 B | $13.19 B | $7.09 B | $13.69 B | $18.21 B |
| Inventories |
|
$5.95 B | $5.91 B | $6.36 B | $6.11 B | - |
| Total Current Assets |
|
$30.27 B | $35.72 B | $32.17 B | $38.78 B | - |
| Property,Plant and Equipment |
|
$19.28 B | $21.42 B | $23.05 B | $23.78 B | - |
| Goodwill |
|
$21.26 B | $21.20 B | $21.20 B | $21.67 B | - |
| Total Assets |
|
$105.69 B | $109.16 B | $106.68 B | $117.11 B | - |
| Total Liabilities |
|
$67.44 B | $63.10 B | $69.04 B | $70.73 B | -$51.91 B |
| Retained Earnings |
|
$53.70 B | $61.08 B | $53.90 B | $63.07 B | - |
| Total Shareholder Equity |
|
$38.18 B | $45.99 B | $37.58 B | $46.31 B | $51.91 B |
| Common Stock |
|
$1.79 B | $1.79 B | $1.79 B | $1.79 B | - |
Merck & Co.'s Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.21 B | $3.91 B | $3.87 B | $4.50 B | - |
| Dividends Payout |
|
-$6.61 B | -$7.01 B | -$7.45 B | -$7.84 B | - |
| Capital Expenditures (Capex) |
|
-$4.45 B | -$4.39 B | -$3.86 B | -$3.37 B | - |
| Free Cash Flow (FCF) |
|
$9.66 B | $14.71 B | $9.14 B | $18.10 B | - |
Merck & Co.'s Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$35.08 B | $41.87 B | $43.99 B | $48.98 B | $52.98 B |
| Gross Profit Margin (%) |
|
72.02% | 70.63% | 73.17% | 76.32% | 81.50% |
| Operating Income |
|
$13.20 B | $18.28 B | $2.95 B | $20.22 B | $26.78 B |
| Operating Income Margin (%) |
|
27.10% | 30.84% | 4.91% | 31.51% | 41.19% |
| Net Income |
|
$13.05 B | $14.52 B | $365.00 M | $17.12 B | $18.25 B |
| Net Income Margin (%) |
|
26.79% | 24.49% | 0.61% | 26.68% | 28.08% |
| EBITDA |
|
$17.90 B | $21.32 B | $6.91 B | $25.71 B | $25.36 B |
| EBITDA Margin (%) |
|
36.75% | 35.95% | 11.49% | 40.06% | 39.01% |
Merck & Co.'s Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
34.17% | 31.57% | 0.97% | 36.96% | 35.17% |
| Return on Assets (ROA) |
|
12.35% | 13.30% | 0.34% | 14.62% | - |
| Debt to Equity |
|
90.70% | 69.55% | 96.51% | 82.63% | 93.79% |
| Debt to total asset |
|
32.77% | 29.30% | 34.00% | 32.68% | 53.21% |
| Enterprise value to revenue |
|
4.53 | 5.06 | 5.22 | 4.32 | 4.06 |
| Enterprise value to EBITDA |
|
12.32 | 14.08 | 45.41 | 10.77 | 12.53 |
| Enterprise value |
|
$220.43 B | $300.22 B | $313.66 B | $276.91 B | $263.93 B |
| Tax Rate (%) |
|
10.96% | 11.66% | 80.04% | 14.06% | 13.31% |
Frequently Asked Questions
